Moody Aldrich Partners LLC Fibrogen Inc Transaction History

Moody Aldrich Partners LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$18.57 - $35.68 $1.05 Million - $2.01 Million	-56,389 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$31.0 - $55.72 $25,575 - $45,969	825 Added 1.48%	56,389 $1.96 Million
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $1,520 - $2,007	41 Added 0.07%	55,564 $2.06 Million
Q3 2020 Nov 12, 2020	BUY	$40.47 - $45.5 $61,595 - $69,251	1,522 Added 2.82%	55,523 $2.28 Million
Q2 2020 Jul 30, 2020	BUY	$32.57 - $42.83 $248,443 - $326,707	7,628 Added 16.45%	54,001 $2.19 Million
Q1 2020 May 07, 2020	BUY	$23.3 - $45.96 $1.08 Million - $2.13 Million	46,373 New	46,373 $1.61 Million
Q4 2018 Feb 12, 2019	SELL	$37.97 - $60.16 $1.28 Million - $2.03 Million	-33,822 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$56.3 - $67.25 $294,054 - $351,246	5,223 Added 18.26%	33,822 $2.06 Million
Q2 2018 Aug 13, 2018	BUY	$44.9 - $64.95 $94,604 - $136,849	2,107 Added 7.95%	28,599 $1.79 Million
Q1 2018 Apr 26, 2018	BUY	$45.35 - $61.65 $281,714 - $382,969	6,212 Added 30.63%	26,492 $1.22 Million
Q4 2017 Jan 31, 2018	BUY	$41.95 - $60.1 $177,238 - $253,922	4,225 Added 26.32%	20,280 $961,000
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $536,237 - $865,364	16,055	16,055 $864,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.